Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 3 Date: 18 Oct 2023
Reviewer's report:
the authors addressed  all questions I'd raised
unfortunately Visible 2 remaines excluded
Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 3 Date: 18 Oct 2023
Reviewer's report:
the authors addressed  all questions I'd raised
unfortunately Visible 2 remaines excluded
Please review this paper.
user
Title: Comparative efficacy and safety of subcutaneous infliximab and vedolizumab in patients
with Crohn’s disease and ulcerative colitis included in randomised controlled trials
Version: 3 Date: 18 Oct 2023
Reviewer's report:
the authors addressed  all questions I'd raised
unfortunately Visible 2 remaines excluded
assistant